LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・Roivant Sciences Ltd

Roivant Sciences Ltd

Gesloten

SectorGezondheidszorg

29.52 -0.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

Max

29.58

Belangrijke statistieken
By Trading Economics
Inkomsten	669M 356M
Verkoop	521K 2.5M
Winstmarge	14,116.825
Werknemers	721
EBITDA	-65M -354M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+27.55% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	1.3B 21B
Vorige openingsprijs	29.92
Vorige sluitingsprijs	29.52

Nieuwssentiment

By Acuity

24%

76%

45 / 344 Rangschikking in Healthcare

Roivant Sciences Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 mei 2026, 16:52 UTC

Belangrijke Nieuwsgebeurtenissen

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mei 2026, 23:57 UTC

Winsten

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q EPS $11.61 >WEBC

26 mei 2026, 21:54 UTC

Winsten

Webco Industries 3Q Sales $179.6M >WEBC

26 mei 2026, 21:48 UTC

Marktinformatie

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mei 2026, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

26 mei 2026, 20:58 UTC

Acquisities, Fusies, Overnames

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 19:22 UTC

Marktinformatie

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mei 2026, 19:17 UTC

Marktinformatie

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mei 2026, 18:56 UTC

Marktinformatie

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mei 2026, 18:03 UTC

Marktinformatie

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mei 2026, 17:42 UTC

Marktinformatie

Grains Await Fresh Trading Catalyst -- Market Talk

26 mei 2026, 17:33 UTC

Marktinformatie

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mei 2026, 17:21 UTC

Marktinformatie

Canada Faces a Labor Market Squeeze -- Market Talk

26 mei 2026, 16:52 UTC

Marktinformatie

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mei 2026, 16:43 UTC

Marktinformatie

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mei 2026, 16:24 UTC

Marktinformatie

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mei 2026, 16:21 UTC

Marktinformatie

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

26 mei 2026, 16:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Auto & Transport Roundup: Market Talk

26 mei 2026, 16:16 UTC

Marktinformatie

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mei 2026, 16:01 UTC

Marktinformatie

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mei 2026, 15:21 UTC

Marktinformatie

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Peer Vergelijking

Prijswijziging

Roivant Sciences Ltd Prognose

Koersdoel

By TipRanks

27.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 37.83 USD 27.55%

Hoogste 42 USD

Laagste 31.5 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Roivant Sciences Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Roivant Sciences Ltd - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

45 / 344 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.